OpenOnco · Treatment Plan

Treatment plan — Ovarian carcinoma

PLAN-BMA-BARD1_GERMLINE_OVARIAN-V1 · v1 · 2026-08-17

Patient

BMA-BARD1_GERMLINE_OVARIAN · Algorithm: ALGO-OVARIAN-ADVANCED-1L

DiagnosisOvarian carcinoma

MOH / ICD-10C56

ICD-O-38441/3; C56, C57.0, C48.1

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
ESCAT: clinical review pendingBIO-HRR-PANEL	BARD1 germline pathogenic	IIB	Molecular evidence option SRC-CIVIC: Level A (Supports, Sensitivity/Response)	BARD1 germline pathogenic in EOC: rare; included in HRR panels; PARPi benefit extrapolated from HRD-positive trial subgroups (PAOLA-1, NOVA non-gBRCA). ESCAT IIB / OncoKB Level 3B.	niraparib maintenance olaparib + bevacizumab (HRD-positive)	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	BRIP1 germline pathogenic	IIA	Molecular evidence option SRC-CIVIC: Level A (Supports, Sensitivity/Response)	BRIP1 (FANCJ) germline pathogenic in EOC: established moderate-risk gene (~RR 3-5); included in HRR panels and HRD-positive PARPi trial subgroups. NCCN includes BRIP1 in PARPi-eligible HRR list. ESCAT IIA / OncoKB Level 3A.	niraparib maintenance olaparib + bevacizumab (HRD-positive) rucaparib (LOH-high)	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	FANCA germline pathogenic (heterozygous)	IIIA	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024 Evidence cited from clinical guidelines; per-source evidence levels not yet structured. See Phase-2-of-CIViC-pivot for re-cite roadmap.	FANCA germline (heterozygous) in EOC: Fanconi-anemia-pathway gene; biallelic loss = Fanconi anemia (recessive). Heterozygous carriers have uncertain cancer risk. FANCA included in some HRR panels (FANCL on PROfound HRR list). PARPi off-label consideration in HRD-positive. ESCAT IIIA / OncoKB Level 3B.	niraparib (HRD-positive) olaparib + bevacizumab	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	FANCL germline pathogenic (heterozygous)	IIIA	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024 Evidence cited from clinical guidelines; per-source evidence levels not yet structured. See Phase-2-of-CIViC-pivot for re-cite roadmap.	FANCL germline (heterozygous) in EOC: Fanconi-anemia-pathway gene; biallelic loss = Fanconi anemia (recessive). Heterozygous carriers have uncertain cancer risk. FANCL included in some HRR panels (FANCL on PROfound HRR list). PARPi off-label consideration in HRD-positive. ESCAT IIIA / OncoKB Level 3B.	niraparib (HRD-positive) olaparib + bevacizumab	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	PALB2 germline pathogenic	IIA	Molecular evidence option SRC-CIVIC: Level A (Supports, Sensitivity/Response)	PALB2 germline pathogenic in EOC: rare (~1%); biologically HR-deficient. Niraparib NOVA non-gBRCA cohort and rucaparib ARIEL3 LOH-high included PALB2; olaparib + bev (PAOLA-1) in HRD-positive includes PALB2. ESCAT IIA / OncoKB Level 3A.	niraparib maintenance olaparib + bevacizumab (HRD-positive) rucaparib maintenance	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	RAD51B germline pathogenic	IIB	Molecular evidence option SRC-CIVIC: Level A (Supports, Sensitivity/Response)	RAD51B germline pathogenic in EOC: confers HR deficiency. RAD51C and RAD51D have established EOC risk; included in HRR panels and HRD-positive PARPi trial subgroups (PAOLA-1, ARIEL3 LOH-high, NOVA non-gBRCA). RAD51B less established. ESCAT IIA-IIB / OncoKB 3A-3B.	niraparib maintenance olaparib + bevacizumab (HRD-positive) rucaparib maintenance	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	RAD51C germline pathogenic	IIA	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024 Evidence cited from clinical guidelines; per-source evidence levels not yet structured. See Phase-2-of-CIViC-pivot for re-cite roadmap.	RAD51C germline pathogenic in EOC: confers HR deficiency. RAD51C and RAD51D have established EOC risk; included in HRR panels and HRD-positive PARPi trial subgroups (PAOLA-1, ARIEL3 LOH-high, NOVA non-gBRCA). RAD51B less established. ESCAT IIA-IIB / OncoKB 3A-3B.	niraparib maintenance olaparib + bevacizumab (HRD-positive) rucaparib maintenance	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	RAD51D germline pathogenic	IIA	Molecular evidence option SRC-CIVIC: Level A (Supports, Sensitivity/Response)	RAD51D germline pathogenic in EOC: confers HR deficiency. RAD51C and RAD51D have established EOC risk; included in HRR panels and HRD-positive PARPi trial subgroups (PAOLA-1, ARIEL3 LOH-high, NOVA non-gBRCA). RAD51B less established. ESCAT IIA-IIB / OncoKB 3A-3B.	niraparib maintenance olaparib + bevacizumab (HRD-positive) rucaparib maintenance	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024
ESCAT: clinical review pendingBIO-HRR-PANEL	RAD54L germline pathogenic	IIIA	Molecular evidence option SRC-CIVIC: Level A (Supports, Sensitivity/Response)	RAD54L germline variants: rare; HR-pathway gene with limited clinical evidence. Included in some HRR panels but no labeled indication. ESCAT IIIA / OncoKB Level 4.	standard therapy PARPi off-label (HRD context only)	SRC-NCCN-OVARIAN-2025 SRC-ESMO-OVARIAN-2024

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-NEG

Regimen

Carboplatin + Paclitaxel (ovarian 3-weekly)

Drugs + NSZU

Carboplatin (DRUG-CARBOPLATIN) AUC 5-6 · IV day 1 every 21d · IV ✓ NSZU covered
Paclitaxel (DRUG-PACLITAXEL) 175 mg/m² · IV day 1 every 21d · IV ✓ NSZU covered

Reason

Primary current-line option selected by ALGO-OVARIAN-ADVANCED-1L at step 6.

Other current-line alternatives (2 tracks)

Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.

Aggressive plan

Indication

IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-OLAP

Regimen

Carboplatin + Paclitaxel (ovarian 3-weekly)

Drugs + NSZU

Carboplatin (DRUG-CARBOPLATIN) AUC 5-6 · IV day 1 every 21d · IV ✓ NSZU covered
Paclitaxel (DRUG-PACLITAXEL) 175 mg/m² · IV day 1 every 21d · IV ✓ NSZU covered

Reason

Current-line alternative presented for HCP consideration

Aggressive plan

Indication

IND-OVARIAN-MAINTENANCE-OLAPARIB

Regimen

Olaparib maintenance (HRD+ ovarian post-platinum response)

Drugs + NSZU

Olaparib (DRUG-OLAPARIB) 300 mg PO BID continuous · Continuous · PO ✓ NSZU covered

Reason

Current-line alternative presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-CBC	Complete Blood Count with Differential	Critical	lab	—	aggressive

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

BRCA1 or BRCA2 pathogenic variant (germline OR somatic) in high-grade serous ovarian carcinoma — ~20-25% prevalence (15% germline + ~7% somatic). Olaparib maintenance after platinum-based 1L (SOLO-1 — mPFS 56.0 vs 13.8 mo BRCA-mut) is treatment-defining; rucaparib + niraparib alternatives. SOLO-2 — 2L+ relapse maintenance.
Tumor-tissue testing identifies somatic BRCA missed by germline-only testing — both germline (blood) AND tumor BRCA testing recommended at diagnosis for all newly diagnosed advanced ovarian. Germline finding triggers cascade testing of…
RF-OVARIAN-BRCA-MUT-ACTIONABLESRC-NCCN-OVARIAN-2025SRC-ESMO-OVARIAN-2024SRC-SOLO1-MOORE-2018
Frailty profile precluding standard carbo+pacli + bev intensified induction in ovarian: ECOG ≥3, OR (age ≥75 + Charlson ≥3), OR composite (age ≥70 + ascites large-volume + albumin <3.0). Triggers carbo-mono OR weekly-dose-dense-pacli (less neuropathy / bone marrow).
EWOC-1 trial: 3-weekly carbo+pacli vs single-agent carbo for frail elderly — combination still won OS but reduced-dose acceptable. Bevacizumab caution in elderly (HTN + GI perforation risk).
RF-OVARIAN-FRAILTY-AGESRC-NCCN-OVARIAN-2025SRC-ESMO-OVARIAN-2024
HRD-positive (BRCA1/2 mutation OR Genomic Instability Score ≥42) high-grade serous ovarian carcinoma. Treatment-defining for PARPi maintenance after platinum-based induction. Olaparib (SOLO-1 BRCA-only, PAOLA-1 with bev) + niraparib (PRIMA all-comer) substantially improve PFS in HRD-positive subset.
HRD testing on FFPE tumor + paired germline. Reflex BRCA → if WT, proceed to GIS scoring. SOLO-1: BRCA-mut maintenance olaparib mPFS 56 vs 14 mo. PAOLA-1: HRD-positive (BRCA-mut OR GIS+) bev+olap mPFS 37 vs 22 mo. PRIMA: niraparib…
RF-OVARIAN-HRD-ACTIONABILITYSRC-NCCN-OVARIAN-2025SRC-ESMO-OVARIAN-2024
Homologous Recombination Deficiency (HRD)-positive high-grade serous ovarian carcinoma (BRCA1/2 mutation OR Genomic Instability Score ≥42). PARPi maintenance after platinum-based induction is treatment-defining: niraparib (PRIMA — mPFS 21.9 vs 10.4 mo HRD-pos), olaparib + bevacizumab (PAOLA-1 — mPFS 37.2 vs 17.7 mo HRD-pos).
HRD assays: Myriad myChoice CDx (companion for olaparib + bev, niraparib), FoundationOne CDx HRD. GIS captures BRCAness (LOH + TAI + LST signatures) in tumors WT for BRCA1/2. HRD-negative HGSC has minimal PARPi maintenance benefit (PRIMA…
RF-OVARIAN-HRD-POSITIVE-ACTIONABLESRC-NCCN-OVARIAN-2025SRC-ESMO-OVARIAN-2024SRC-PRIMA-GONZALEZ-MARTIN-2019
Suboptimal primary cytoreductive surgery (residual disease ≥1 cm) or unresectable at presentation in advanced (FIGO III-IV) ovarian carcinoma. MDT-trigger for neoadjuvant chemo (NACT) → interval debulking surgery (IDS) pathway per CHORUS / EORTC55971 trials, rather than primary debulking.
Surgical-vs-NACT timing decision is the central MDT debate in advanced ovarian. Fagotti laparoscopic score predicts complete resection feasibility. Complete (R0) cytoreduction substantially improves PFS/OS — when achievable, primary…
RF-OVARIAN-SUBOPTIMAL-DEBULKINGSRC-NCCN-OVARIAN-2025SRC-ESMO-OVARIAN-2024

CONTRA-AGGRESSIVE

Hard contraindications to escalation

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Standard plan (IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-NEG)

Do NOT use olaparib maintenance in HRD-negative — minimal benefit, MDS/AML risk
Do NOT initiate bev maintenance within 28 days of major surgery

Aggressive plan (IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-OLAP)

Do NOT skip HRD testing — defines maintenance choice (PARPi-only HRD+; niraparib-all-comer if HRD-negative weak benefit)
Do NOT start olaparib without confirmed CR/PR to platinum induction
Do NOT continue olaparib through Grade 3 anemia without dose reduction

Aggressive plan (IND-OVARIAN-MAINTENANCE-OLAPARIB)

Do NOT start without confirmed CR/PR to platinum
Do NOT continue past 2 years for non-BRCA HRD+ unless still benefiting (label allows ≤24 mo)
Do NOT skip pre-treatment counseling on long-term MDS/AML risk

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Carboplatin + Paclitaxel (ovarian 3-weekly)

21-day cycles × 6 cycles (per GOG-218 / ICON-7 induction); subsequent maintenance per HRD/biomarker stratification

MDT brief

Discussion questions (2, 0 blocking)

OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
OQ-BIOMARKER-HRD-STATUS
What is the status of Homologous recombination deficiency (HRD) status (BIO-HRD-STATUS)? It is required by track(s): IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-OLAP, IND-OVARIAN-MAINTENANCE-OLAPARIB. Expected value: HRD-positive.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ molecular_geneticist

MDT talk tree (3 steps)

#	Owner	Topic	Action
1	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
2	molecular_geneticist	Biomarker status	What is the status of Homologous recombination deficiency (HRD) status (BIO-HRD-STATUS)? It is required by track(s): IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-OLAP, IND-OVARIAN-MAINTENANCE-OLAPARIB. Expected value: HRD-positive.
3	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (recommended) — for consideration (2)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
Molecular geneticist / molecular oncologist recommended
Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.
Owns: OQ-BIOMARKER-HRD-STATUS

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 0/1 known (0%), 1 missing, 0 default-track gaps
Unevaluated RedFlags: RF-BARD1-CONFIRMED-CARRIER, RF-BARD1-FAMILY-HISTORY-SUSPICION, RF-BRCA-CONFIRMED-CARRIER, RF-BRCA-HBOC-FAMILY-HISTORY-SUSPICION, RF-BREAST-OVARIAN-HRD-ASSAY-DISTINCTION, RF-BRIP1-CONFIRMED-CARRIER, RF-BRIP1-FAMILY-HISTORY-SUSPICION, RF-CASCADE-BRCA-FDR-POSITIVE, RF-CASCADE-LYNCH-FDR-POSITIVE, RF-DICER1-CONFIRMED-CARRIER, RF-LYNCH-CONFIRMED-CARRIER, RF-LYNCH-FAMILY-HISTORY-SUSPICION, RF-OCC-ASBESTOS-MALIGNANCY-PREVENTION, RF-OVARIAN-BRCA-MUT-ACTIONABLE, RF-OVARIAN-FRA-HIGH-ACTIONABLE, RF-OVARIAN-FRAILTY-AGE, RF-OVARIAN-HRD-ACTIONABILITY, RF-OVARIAN-HRD-POSITIVE-ACTIONABLE, RF-OVARIAN-INFECTION-SCREENING, RF-OVARIAN-PERIOPERATIVE-VTE, RF-OVARIAN-PLATINUM-RESISTANT, RF-OVARIAN-PLATINUM-SENSITIVE, RF-OVARIAN-SUBOPTIMAL-DEBULKING, RF-OVARIAN-TRANSFORMATION-PROGRESSION, RF-PALB2-CONFIRMED-CARRIER, RF-PALB2-FAMILY-HISTORY-SUSPICION, RF-PAN-BRCA-SOMATIC-PARPI-CANDIDATE, RF-PEUTZ-JEGHERS-CONFIRMED-CARRIER, RF-PEUTZ-JEGHERS-FAMILY-HISTORY-SUSPICION, RF-RAD51C-D-CONFIRMED-CARRIER, RF-RAD51C-D-FAMILY-HISTORY-SUSPICION, RF-REPRODUCTIVE-BREAST-ENDOMETRIAL-PREVENTION, RF-REPRODUCTIVE-ENDOMETRIOSIS-OVARIAN-PREVENTION, RF-REPRODUCTIVE-OCP-LONG-TERM

Missing biomarker	Label	MDT owner	Default track	Required by	Next action
`BIO-HRD-STATUS`	Homologous recombination deficiency (HRD) status	molecular_geneticist	no	IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-OLAP, IND-OVARIAN-MAINTENANCE-OLAPARIB	Verify result, method, specimen, and report date before sign-off. Expected/constraint: HRD-positive

Technical MDT skill metadata (2/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-ESMO-OVARIAN-2024: ESMO Ovarian Cancer Clinical Practice Guideline (2024)
SRC-NCCN-OVARIAN-2025: NCCN Ovarian Cancer (v.2.2025)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-08-17.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT07667192	Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer	N/A	RECRUITING	Affidea Nu-med Center of Oncological DIagnostics and Therapy	—	Surrogate endpoint only Single country
NCT06735326	Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer	PHASE2	RECRUITING	Qilu Hospital of Shandong University	—	Surrogate endpoint only Single country
NCT06890338	A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.	PHASE2	RECRUITING	AbbVie	—	Surrogate endpoint only Single country
NCT06855706	An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study	NA	RECRUITING	Roswell Park Cancer Institute	—	Single country
NCT07244835	A Study of DEG6498 in Participants With Solid Tumors	PHASE1	RECRUITING	Degron Therapeutics Co.	—	Phase 1 only Single country
NCT05721976	With Love, Grandma ("Con Cariño, Abuelita") Pilot Study	NA	RECRUITING	University of Miami Sylvester Comprehensive Cancer Center	—	Single country
NCT06172478	A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING	Daiichi Sankyo	—	Surrogate endpoint only
NCT03604315	Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF	PHASE1	RECRUITING	M.D. Anderson Cancer Center	—	Phase 1 only Single country
NCT03702309	Liquid Biopsy Evaluation and Repository Development at Princess Margaret	N/A	RECRUITING	University Health Network, Toronto	—	Single country
NCT07749586	A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors	PHASE1 / PHASE2	RECRUITING	Arvinas Inc.	—	Surrogate endpoint only Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan Carboplatin + Paclitaxel (ovarian 3-weekly) (REG-CARBO-PACLI-OVARIAN)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan Carboplatin + Paclitaxel (ovarian 3-weekly) (REG-CARBO-PACLI-OVARIAN)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan Olaparib maintenance (HRD+ ovarian post-platinum response) (REG-OLAPARIB-MAINT-OVARIAN)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT07667192 Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06735326 Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06855706 An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07244835 A Study of DEG6498 in Participants With Solid Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05721976 With Love, Grandma ("Con Cariño, Abuelita") Pilot Study No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06172478 A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03604315 Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03702309 Liquid Biopsy Evaluation and Repository Development at Princess Margaret No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07749586 A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-08-17.

plan_id: PLAN-BMA-BARD1_GERMLINE_OVARIAN-V1 | version: 1 | generated: 2026-08-17T08:06:31.481653+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.